Filing Overview
Allogene Therapeutics, Inc. filed a Form 8-K dated May 18, 2021 under Item 5.02 regarding compensation changes for Rafael Amado, M.D., Chief Medical Officer and Executive Vice President of Research and Development. The filing was signed on May 20, 2021.
Business Context and Reporting Period
The filing concerns executive compensation and retention in connection with progress across Allogene’s allogeneic CAR T-cell therapy pipeline. It does not report quarterly or annual operating results.
Key Financial and Compensation Metrics
- Annual base salary: Increased from $525,000 to $600,000 for the remainder of 2021.
- Equity award: Grant of 200,534 restricted stock units.
- Vesting: 33,422 units vest after one year, 66,844 after two years, and 100,268 after three years.
- Revenue, profit, cash flow, margins, debt, and liquidity: The filing text does not provide financial statement metrics or a clear value for these items.
Material Changes and Management Commentary
The Compensation Committee described Dr. Amado’s achievements in 2021 as extraordinary and characterized the compensation changes as a retention measure. The cited achievements included:
- Initiation of the ALLO-316 clinical trial in advanced or metastatic clear cell renal cell carcinoma.
- Advancement of the TurboCAR technology platform and clearance of an IND for ALLO-605 in relapsed/refractory multiple myeloma.
- Advancement of positive clinical data for ALLO-501 and ALLO-501A in relapsed/refractory non-Hodgkin lymphoma.
Outlook, Risks, and Unusual Items
Management cited plans for rapid pipeline advancement, including the potential initiation of a planned pivotal trial of ALLO-501A at the end of 2021 and a potential future submission for approval of ALLO-501A. These are forward-looking plans and are subject to clinical, regulatory, operational, and other development risks. The filing does not provide detailed risk factors, financial guidance, or contingencies.
Investor Verification Checklist
- Verify the effective date and terms of the salary increase for the remainder of 2021.
- Review the restricted stock unit agreement and confirm vesting conditions and any forfeiture provisions.
- Assess potential future share dilution from the 200,534-unit equity award.
- Verify the status and timing of the ALLO-316, ALLO-605, ALLO-501, and ALLO-501A programs in subsequent filings.
- Confirm whether the planned ALLO-501A pivotal trial and potential regulatory submission occurred as anticipated.